User profiles for V. LOUSTAUD

Véronique Loustaud-Ratti

Professeur d'hépatologie CHU Limoges, université Limoges
Verified email at unilim.fr
Cited by 8707

Role of iron in the pathogenesis of respiratory disease

…, F Abbasian, MR Starkey, V Loustaud-Ratti… - The international journal …, 2017 - Elsevier
Iron is essential for many biological processes, however, too much or too little iron can result
in a wide variety of pathological consequences, depending on the organ system, tissue or …

[HTML][HTML] Ribavirin: Past, present and future

V Loustaud-Ratti, M Debette-Gratien… - World journal of …, 2016 - ncbi.nlm.nih.gov
Before the advent of direct acting antiviral agents (DAAs) ribavirin, associated to pegylated-interferon
played a crucial role in the treatment of chronic hepatitis C, preventing relapses …

Extrahepatic manifestations associated with hepatitis C virus infection: a prospective multicenter study of 321 patients

…, E Rosenthal, P Cohen, I Loury, V Loustaud-Ratti… - Medicine, 2000 - journals.lww.com
In the years following the identification and advancement of hepatitis C virus (HCV) serum
assay tests, extrahepatic manifestations associated with chronic infections were described, …

On the separation of net ecosystem exchange into assimilation and ecosystem respiration: review and improved algorithm

M Reichstein, E Falge, D Baldocchi… - Global change …, 2005 - Wiley Online Library
This paper discusses the advantages and disadvantages of the different methods that
separate net ecosystem exchange (NEE) into its major components, gross ecosystem carbon …

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) …

…, G Riachi, PH Bernard, V Loustaud-Ratti… - Journal of …, 2013 - Elsevier
Background & Aims In phase III trials, the safety profile of triple therapy (pegylated interferon/ribavirin
with boceprevir or telaprevir) seems to be similar in HCV treatment-experienced …

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

…, A Abergel, P Calès, N Ganne, V Loustaud-Ratti… - The Lancet, 2019 - thelancet.com
Background Although direct-acting antivirals have been used extensively to treat patients
with chronic hepatitis C virus (HCV) infection, their clinical effectiveness has not been well …

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a …

…, D Guyader, JD Grangé, V Loustaud-Ratti… - The Lancet Infectious …, 2015 - thelancet.com
Background Patients with cirrhosis resulting from chronic hepatitis C virus (HCV) infection
are at risk of life-threatening complications, but consistently achieve lower sustained …

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis

…, P Marcellin, G Riachi, PH Bernard, V Loustaud–Ratti… - Gastroenterology, 2014 - Elsevier
Background & Aims We investigated the effectiveness of the protease inhibitors peginterferon
and ribavirin in treatment-experienced patients with hepatitis C virus (HCV) genotype 1 …

Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients

…, F Herrmann, K Ly, PY Robert, V Loustaud… - The American journal of …, 2001 - Elsevier
OBJECTIVE: To determine the risk factors—especially the effects of thrombocytosis—for
permanent visual loss in patients with temporal arteritis. METHODS: One hundred seventy-four …

Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases

M Ramos-Casals, V Loustaud-Ratti, S De Vita… - Medicine, 2005 - journals.lww.com
To define the clinical and immunologic pattern of expression of Sjögren syndrome (SS)
associated with chronic hepatitis C virus (HCV) infection, we conducted a multicenter study …